Related Experiment Video
Updated: May 5, 2026
07:35
Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection
Published on: June 8, 2020
6.5K
Molecular diagnostics in colorectal carcinoma
Amarpreet Bhalla1, Muhammad Zulfiqar, Michael Weindel
1Pathology Department, Harper University Hospital, Detroit Medical Center, Wayne State University School of Medicine, 3990 John R Street, Detroit, MI 48201, USA.
Clinics in Laboratory Medicine
|November 26, 2013
Summary
Understanding colorectal cancer (CRC) molecular pathogenesis is key. Genetic testing, including microsatellite instability and BRAF mutation analysis, aids in diagnosing Lynch syndrome and guiding CRC treatment.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Colorectal carcinoma (CRC) pathogenesis involves distinct pathways: the traditional adenoma-carcinoma sequence, the serrated polyp pathway, and microsatellite instability.
- Hereditary nonpolyposis colorectal cancer (Lynch syndrome) is driven by specific genetic mutations.
- Accurate molecular classification is crucial for understanding CRC progression and patient stratification.
Purpose of the Study:
- To review the molecular pathogenesis and classification of colorectal carcinoma.
- To highlight genetic testing strategies for Lynch syndrome.
- To discuss current and potential molecular markers and screening approaches for CRC.
Main Methods:
- Review of established models (Vogelstein, serrated polyp pathway, microsatellite instability).
- Analysis of genetic testing components for Lynch syndrome (microsatellite instability, methylator phenotyping, BRAF, KRAS mutations).
- Evaluation of molecular markers (RT-PCR, nucleic acid amplification) and screening methods (stool DNA).
Main Results:
- Molecular pathogenesis is understood through multiple pathways, with genetic mutations underpinning hereditary forms like Lynch syndrome.
- Genetic testing for Lynch syndrome integrates microsatellite instability, BRAF/KRAS mutation analysis, and other molecular assays.
- Emerging biomarkers and stool DNA-based screening show promise for early detection and molecular characterization of CRC.
Conclusions:
- Molecular insights have refined the understanding and classification of colorectal carcinoma.
- Genetic and molecular testing are essential for diagnosing hereditary CRC syndromes and informing personalized treatment.
- Continued research into novel biomarkers and screening technologies will improve CRC management.
